About Embecta
Embecta is a company based in Parsippany (United States) founded in 2022. The company has 2,100 employees as of September 30, 2024. Embecta has completed 1 acquisition, including Owen Mumford. Embecta offers products and services including Pen Needles and Insulin Syringes.
- Headquarter Parsippany, United States
- Employees 2100 as on 30 Sep, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Embecta Corp.
-
Annual Revenue
$1.08 B (USD)-3.8as on Sep 30, 2025
-
Net Profit
$95.4 M (USD)21.84as on Sep 30, 2025
-
EBITDA
$380.4 M (USD)75.54as on Sep 30, 2025
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
2100
as on Sep 30, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Embecta
Embecta is a publicly listed company on the NASDAQ with ticker symbol EMBC in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Embecta
Embecta offers a comprehensive portfolio of products and services, including Pen Needles and Insulin Syringes.
Pen needles are manufactured for use in insulin delivery to aid diabetes management.
Insulin syringes are supplied for administering insulin as part of diabetes care practices.
People of Embecta
Unlock access to complete
Leadership Team
15 people
Human Resources and Administration
14 people
Finance and Accounting
13 people
Legal and Compliance
7 people
Sales and Marketing
6 people
Software Development Team
6 people
Operations Team
2 people
Regional Team
2 people
Unlock access to complete
Funding Insights of Embecta
Detailed funding history for Embecta
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Embecta
Embecta has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Owen Mumford.
Investment portfolio details for Embecta
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Disposables for drug delivery and capillary blood sampling are manufactured.
|
Locked | Locked | 1952 | Locked |
Complete acquisition details for Embecta
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Embecta
Detailed financials for Embecta
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Embecta Comparisons
Peer comparison for Embecta
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Embecta
Detailed competitors of Embecta
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Embecta
Complete news archive for Embecta
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Embecta
Embecta was founded in 2022.
Embecta is headquartered in Parsippany, United States. It is registered at Parsippany, New Jersey, United States.
Devdatt Kurdikar is the current CEO of Embecta.
As of Sep 30, 2024, the latest employee count at Embecta is 2,100.
Annual revenue of Embecta is $1.08B as on Sep 30, 2025.
Embecta was founded in 2022 and is headquartered in Parsippany, United States. Operations are centered in the healthcare sector, with a focus on diabetes management. Insulin delivery products such as pen needles and syringes are developed and supplied to support daily care needs. Efforts are directed toward enhancing injection experiences through innovation. Educational resources and guidance on proper injection techniques are also made available to users.
Embecta offers Pen Needles and Insulin Syringes.
Yes, Embecta is publicly traded on NASDAQ under the ticker symbol EMBC.
Embecta has made 1 acquisition, including Owen Mumford.
The ticker symbol of Embecta is EMBC on NASDAQ.